Skip to content

Released May 7, 2020, after the close

10-Q filed May 11, 2020, 41 days after period end · 0001162194-20-000042

Q1 2020 · 10-Q
Revenue$27.62M−8.3% vs Q1 2019−14.9% vs Q4 2019
Net Income-$15.98MN/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$0.23N/M vs Q1 2019N/M vs Q4 2019
Gross Profit$13,002,000−23.5%
Operating Income-$14,942,000N/M
Operating Cash Flow-$4,295,000N/M
Free Cash Flowderived-$5,325,000N/M
Margins · derived
Gross margin47.1%−9.3 pt vs Q1 2019
Operating margin-54.1%−6.9 pt vs Q1 2019
Net margin-57.9%+26.7 pt vs Q1 2019

What the release said

The release

Same quarter

MetricQ1 2020Q1 2019Q1 2018Q1 2017
Revenue$27.62M$30.11M$25.25M$25.53M
Net Income-$15.98M-$25.47M-$13.25M-$17.20M
EPS Diluted-$0.23-$0.44-$0.34-$0.59

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR